ABT vs TVTX: fair value comparison
Abbott Laboratories and Travere Therapeutics, Inc. · Updated 2026-10-19
TVTX is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, TVTX currently ranks higher by quality score.
| ABT | TVTX | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $99.60 | $49.60 |
| 12-month range | $82.56–$130.59 | $26.79–$67.52 |
| Rank by discount to fair value | #26 of 108 Healthcare | — |
| Rank by quality score | #73 of 301 Healthcare | #72 of 301 Healthcare |
| Quality grade | B | B |
| Leverage | Moderate | High |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ABT fair value analysis · TVTX fair value analysis